NCT02482857View on ClinicalTrials.gov

Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Coronary Artery Bypass SurgeryStable Angina
Interventions
DRUG

Acetylsalicylic acid

To compare BID dosing with OD dosing with clinically used aspirin dosages.

All Listed Sponsors
collaborator

Karolinska Institutet

OTHER

lead

Karolinska University Hospital

OTHER

NCT02482857 - Optimal Dose of Acetylsalicylic Acid After Coronary Artery Bypass Grafting | Biotech Hunter | Biotech Hunter